TCRT · Insider Trading
Alaunos Therapeutics, Inc. Common Stock
Every open-market purchase and sale reported by TCRT officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-08 | Robert W Postma | Director | A | +21,829 | +$16.25K |
| 2026-10-08 | Michael Allen Jerman | Director | A | +20,990 | +$15.62K |
| 2026-10-08 | Holger Weis | CEO | A | +23,564 | +$17.54K |
| 2026-10-08 | Jaime Vieser | Director | A | +22,669 | +$16.87K |
| 2026-08-11 | Holger Weis | CEO | A | +4,363 | +$8.77K |
| 2026-07-27 | Holger Weis | CEO | A | +4,568 | +$8.77K |
| 2026-07-27 | Michael Allen Jerman | Director | A | +8,138 | +$15.62K |
| 2026-07-27 | Robert W Postma | Director | A | +8,463 | +$16.25K |
| 2026-07-27 | Jaime Vieser | Director | A | +8,789 | +$16.87K |
| 2026-07-02 | Holger Weis | Chief Executive Officer | A | +3,880 | +$8.77K |
| 2026-06-17 | Holger Weis | Chief Executive Officer | A | +7,761 | +$17.54K |
| 2026-05-27 | Holger Weis | Chief Executive Officer | A | +3,700 | +$8.77K |
| 2026-05-01 | Michael Allen Jerman | Director | A | +6,032 | +$15.62K |
| 2026-05-01 | Robert W Postma | Director | A | +6,274 | +$16.25K |
| 2026-05-01 | Jaime Vieser | Director | A | +6,515 | +$16.87K |
| 2026-01-15 | Michael Allen Jerman | Director | A | +5,406 | +$15.62K |
| 2026-01-15 | Jaime Vieser | Director | A | +5,839 | +$16.87K |
| 2026-01-15 | Robert W Postma | Director | A | +5,622 | +$16.25K |
| 2025-11-26 | Robert W Postma | Director | A | +5,142 | +$16.25K |
| 2025-11-26 | Michael Allen Jerman | Director | A | +4,183 | +$13.22K |
| 2025-11-26 | Jaime Vieser | Director | A | +5,340 | +$16.87K |
| 2025-08-20 | Holger Weis | Chief Executive Officer | A | +13,676 deriv. | — |
| 2025-08-20 | Ferdinand Groenewald | Vice President of Finance | A | +10,775 | — |
| 2025-07-17 | Michael Allen Jerman | Director | A | +13,200 deriv. | — |
| 2025-07-07 | Holger Weis | Chief Executive Officer | A | +130,000 deriv. | — |
| 2025-07-07 | Jaime Vieser | Director | A | +3,400 | — |
| 2025-07-07 | Robert W Postma | Director | A | +4,050 | — |
| 2025-06-26 | Jaime Vieser | Director | Buy | +250 deriv. | — |
| 2025-06-26 | Robert W Postma | Director | A | +20,804 | +$60.75K |
| 2025-04-15 | Holger Weis | Director | A | +10,904 deriv. | — |
| 2025-04-15 | Robert W Postma | Director | A | +20,804 | +$60.75K |
| 2025-04-15 | Jaime Vieser | Director | A | +17,465 | — |
| 2025-04-01 | Ferdinand Groenewald | VP, Finance | A | +3,000 deriv. | — |
| 2025-04-01 | Melinda Lackey | Legal & Administration | A | +1,000 deriv. | — |
| 2025-04-01 | Dale Curtis Hogue Jr. | See Remarks | A | +3,000 deriv. | — |
| 2025-01-03 | Jaime Vieser | Director | Sell | −3,000 | −$6.02K |
| 2024-08-16 | Melinda Lackey | Legal & Administration | A | +1,500 deriv. | — |
| 2024-08-16 | Ferdinand Groenewald | VP, Finance | A | +1,500 deriv. | — |
| 2024-06-10 | Robert W Postma | Director | A | +12,800 deriv. | — |
| 2024-06-10 | Robert Hofmeister | Director | A | +12,800 deriv. | — |
| 2024-06-10 | Jaime Vieser | Director | A | +12,800 deriv. | — |
| 2024-06-10 | Holger Weis | Director | A | +23,724 deriv. | — |
| 2024-01-23 | Dale Curtis Hogue Jr. | Interim CEO | A | +600,000 deriv. | — |
| 2024-01-03 | Dale Curtis Hogue Jr. | Director | A | +191,667 deriv. | — |
| 2023-09-05 | Kevin S. Boyle Sr. | Chief Executive Officer | Sell | −68,014 | −$9.54K |
| 2023-06-08 | Mary Thistle | Director | A | +100,000 deriv. | — |
| 2023-06-08 | Holger Weis | Director | A | +100,000 deriv. | — |
| 2023-06-08 | Robert W Postma | Director | A | +100,000 deriv. | — |
| 2023-06-08 | Jaime Vieser | Director | A | +100,000 deriv. | — |
| 2023-06-08 | James Huang | Director | A | +100,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Jaime Vieser | Director | 83,814 | $178.52K |
| Robert W Postma | Director | 80,462 | $171.38K |
| Holger Weis | CEO | 49,054 | $104.49K |
| Michael Allen Jerman | Director | 44,749 | $95.32K |
| Ferdinand Groenewald | Vice President of Finance | 10,775 | $22.95K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the TCRT quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.